Role of aldosterone in congestive heart failure

References

• Villarreal D, freeman RH. ANF and the renin-angiotensin system in the regulation of sodium balance: longitudinal studies in experimental heart failure. J Lab Clin Med 1991: 118(6): 515–22
   PubMed Web of Science ®Google Scholar
• Bauer JH. Angiotensin converting enzyme inhibitors. Am J Hypertens 1990: 3(4): 331–7
   PubMed Web of Science ®Google Scholar
• Deedwania PC Angiotensin-converting enzyme inhibitors in congestive heart failure. Arch Intern Med 1990: 150(9): 1798–805
   PubMedGoogle Scholar
• Tofbvic SP Pong AS, Jackson EK Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension 1991: 18(6): 774–82
   PubMed Web of Science ®Google Scholar
• Yankopoulus NA, Davis JO, Kliman B, et al. Evidence that a humoral agent stimulates the adrenal cortex to secrete aldosterone in experimental secondary hyperaldosteronism. J Clin Invest 1959: 38: 1278–89
   PubMed Web of Science ®Google Scholar
• Davis JO, Carpenter CC, Ayers CR, et al. Evidence for secretion of an aldosterone-stimulating hormone by the kidney. J Clin Invest 1961: 40(Apr): 684–96
   PubMed Web of Science ®Google Scholar
• Davis JO, Ayrrs CR, Carpenter CC. Renal origin of an aldosterone-stimulating hormone in dogs with thoracic constriction and in sodium- depleted dogs. J Clin Invest 1961;40(Aug): 1466–74
   PubMed Web of Science ®Google Scholar
• Davis JO. Adrenocortical and renal hormonal function in experimental cardiac failure. Circulation 1962: 25(Jun): 1002–14
   PubMedGoogle Scholar
• Davis JO, Hartroft PM, Titus EO, et al. The role of the renin-angiotensin system in the control of aldosterone secretion. J Clin Invest 1962: 4(Feb): 378–89
   Web of Science ®Google Scholar
• Liddle GW, Duncan LE, Bartter FC. Dual mechanism regulating adrenocortical function in man. Am J Med 1956: 21: 380–6
   PubMed Web of Science ®Google Scholar
• Conn JW. Aldosteronism and hypertension: primary aldosteronism versus hypertensive disease with secondary aldosteronism. Arch Intern Med 1961: 107(Jun): 813–28
   PubMedGoogle Scholar
• Laragh JH, Ulick S, Januszewicz V, et al. Aldosterone secretion and primary and malignant hypertension. J Clin Invest 1960: 39(Jul): 1091–106
   PubMed Web of Science ®Google Scholar
• Bonvalet JP, Doignon I, Blot-Chabaud M, et al. Distribution of 11 beta-hydroxysteroid dehydrogenase along the rabbit nephron. J Clin Invest 1990: 86(3): 832–7
   PubMed Web of Science ®Google Scholar
• Davis JO, Freeman RH. The other angiotensins. Biochem Pharmacol 1977: 26(2): 93–7
   PubMed Web of Science ®Google Scholar
• Davies DL, Beevers DG, Brown JJ, et al. Aldosterone and its stimuli in normal and hypertensive man: are essential hypertension and primary hyperaldosteronism without tumour the same condition? J Endocrinol 1979: 81(2): 79–91P
   Google Scholar
• Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982: 4(6): 966–72
   PubMed Web of Science ®Google Scholar
• Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981: 91(3): 457–65
   PubMed Web of Science ®Google Scholar
• Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther 1986: 9(1): 63–76
   PubMed Web of Science ®Google Scholar
• Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neurocndocrine effects of introducing diuretics. Br Heart J 1987: 57(1): 17–22
   PubMedGoogle Scholar
• Peltola P, Lahovaara S, Paasonen MK. Effect of furosemide and hydrochlorothiazide on plasma renin activity in man. Ann Med Exp Biol Fenn 1970: 48(2): 122–4
   PubMedGoogle Scholar
• Azukizawa S, Iwasaki I, Kigoshi T, et al. Effects of heparin treatments in vivo and in vitro on adrenal angiotensin II receptors and angiotensin II-induced aldosterone production in rats. Acta Endocrinol (Copenh) 1988: 119(3): 367–72
   PubMedGoogle Scholar
• Wilson ID, Goetz FC. Selective hypoaldosteronism after prolonged heparin administration: a case report with postmortem findings. Am J Med 1964: 36(Apr): 635–40
   PubMed Web of Science ®Google Scholar
• Yamakita N, Chiou S, Gomez-Sanchez CE. Inhibition of aldosterone biosynthesis by 18-ethynyl-deoxycorticosterone. Endocrinology 1991: 129(5): 2361–6
   PubMed Web of Science ®Google Scholar
• Tait JF, Bougas J, Little B, et al. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol 1965: 25(Feb): 219–28
   Google Scholar
• Laragh JH. Endocrine mechanisms in congestive cardiac failure: renin, aldosterone and atrial natriuretic hormone. Drugs 1986: 32 (Suppl 5): 1–12
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Vcress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981: 28(1): 89–94
   PubMed Web of Science ®Google Scholar
• Goetz KL. Physiology and pathophysiology of atrial peptides. Am J Physiol 1988: 254 (1 Pt 1): E1–15
   PubMed Web of Science ®Google Scholar
• Salto Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 1989: 83(1): 298–305
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H, Horike K, et al. Ventricular expression of atrial natriuretic polypeptide and its relations with hemodynamics and histology in dilated human hearts: immunohistochemical study of the endomyocardial biopsy specimens. Circulation 1989: 80(5): 1137–47
   PubMed Web of Science ®Google Scholar
• Ding J, Thibault G, Gutkowska J, et al. Cardiac and plasma atrial natriuretic factor in experimental congestive heart failure. Endocrinology 1987: 121 (1): 248–57
   PubMed Web of Science ®Google Scholar
• Cogan MG. Atrial natriuretic peptide. Kidney Int 1990: 37(4): 1148–60
   PubMed Web of Science ®Google Scholar
• Inagami T. Atrial natriuretic factor. J Biol Chem 1989: 264(6): 3043–6
   PubMed Web of Science ®Google Scholar
• Hackenthal E, Paul M, Ganten D, et al. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 1990: 70(4): 1067–116
   PubMed Web of Science ®Google Scholar
• Villarreal D, Freeman RH, Brands MW. ANF and postprandial control of sodium excretion in dogs with compensated heart failure. Am J Physiol 1990: 258(1 Pt2): R232–9
   PubMed Web of Science ®Google Scholar
• Villarreal D, Freeman RH, Davis JO, et al. Atrial natriuretic factor secretion in dogs with experimental high-output heart failure. Am J Physiol 1987: 252(4 Pt 2): H692–6
   PubMed Web of Science ®Google Scholar
• Villarreal D, Freeman RH, Brands MW. DOCA administration and atrial natriuretic factor in dogs with chronic heart failure. Am J Physiol 1989: 257(3 Pt 2): H739–45
   PubMed Web of Science ®Google Scholar
• Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986: 231(4742): 1145–7
   PubMed Web of Science ®Google Scholar
• Eiskjaer H, Bagger JP, Danielsen H, et al. Mechanisms of sodium retention in heart failure: relation to the renin-angiotensin-aldosterone system. Am J Physiol 1991: 260(6 Pt 2): F883–9
   PubMed Web of Science ®Google Scholar
• Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989: 80(2): 299–305
   PubMed Web of Science ®Google Scholar
• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991: 83(6): 1849–65
   PubMed Web of Science ®Google Scholar
• Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation 1990: 82(5): 1730–6
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990: 82(5): 1724–9
   PubMed Web of Science ®Google Scholar
• Nicholls MG, Espincr EA, Donald RA, et al. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med 1974: 47(4): 301–15
   PubMedGoogle Scholar
• Kubo SH, Clark M. Laragh JH, et al. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol 1987: 60(16): 1322–8
   PubMed Web of Science ®Google Scholar
• Villarreal D, Freeman RH, Johnson RA. Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure. Am J Physiol 1992: 262(3 Pt 2): R509–16
   PubMed Web of Science ®Google Scholar
• Michorowski B, Ceremuzynski L. The renin-angiotensin-aldosterone system and the clinical course of acute myocardial infarction. Eur Heart J 1983: 4(4): 259–64
   PubMed Web of Science ®Google Scholar
• Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 1990: 66(5): 529–32
   PubMed Web of Science ®Google Scholar
• Mooser V, Wacbcr G, Bidiville J, et al. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic. J Clin Hypertens 1987: 3(4): 510–3
   PubMed Web of Science ®Google Scholar
• Schohn DC, Spiesscr R, Wehden M, et al. Aldactazine/captopril combination, safe and effective in mild to moderate systemic hypertension: report on a multicenter study of967 patients. Am J Cardiol 1990: 65(23): 4–6K
   Web of Science ®Google Scholar
• Brilla CG, Weber KT. Prevention of myocardial fibrosis in renovascular hypertension and hyperaldosteronism: anti-fibrotic effects of spironolactone. (Abstr) Proceedings of 17th International Aldosterone Conference. Evaraville, Ind: Meetings & Events Communications, 1991: 56–7
   Google Scholar
• Sheehan JP, Seelig MS. Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium 1984: 3(4- 6): 301–14
   PubMedGoogle Scholar
• Dyckner T. Relation of cardiovascular disease to potassium and magnesium deficiencies. Am J Cardiol 1990: 65(23): 44–6K
   Web of Science ®Google Scholar